ERR2598166
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_forebrain
- 4
- umap1_2d
- -2.136630635
- umap2_2d
- -1.101292179
- umap1_3d
- -4.195820285
- umap2_3d
- 3.457393124
- umap3_3d
- -1.563502074
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.680
- MYC_TARGETS_V2+0.680
- G2M_CHECKPOINT+0.630
- MYC_TARGETS_V1+0.580
- WNT_BETA_CATENIN_SIGNALING+0.430
- ANGIOGENESIS+0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.390
- MITOTIC_SPINDLE+0.350
- MTORC1_SIGNALING+0.350
- TGF_BETA_SIGNALING+0.350
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.370
- INTERFERON_ALPHA_RESPONSE-0.310
- COMPLEMENT-0.200
- INTERFERON_GAMMA_RESPONSE-0.200
- ADIPOGENESIS-0.190
- KRAS_SIGNALING_UP-0.170
- BILE_ACID_METABOLISM-0.150
- P53_PATHWAY-0.150
- PEROXISOME-0.130
- HEDGEHOG_SIGNALING-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598171 | fetal | fetal | 0.961 |
| 2 | ERR2598170 | fetal | fetal | 0.959 |
| 3 | ERR2598180 | fetal | fetal | 0.947 |
| 4 | ERR2598164 | fetal | fetal | 0.940 |
| 5 | ERR2598184 | fetal | fetal | 0.938 |
| 6 | ERR2598165 | fetal | fetal | 0.938 |
| 7 | ERR2598181 | fetal | fetal | 0.912 |
| 8 | ERR2598197 | fetal | fetal | 0.876 |
| 9 | ERR2598207 | fetal | fetal | 0.872 |
| 10 | ERR2598169 | fetal | fetal | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.680 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.680 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.630 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.580 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.430 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.410 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |